AACR 2016

Adding Galunisertib to Gemcitabine Improves OS, PFS in Pancreatic Cancer

Adding Galunisertib to Gemcitabine Improves OS, PFS in Pancreatic Cancer

By

The addition of galunisertib to gemcitabine demonstrated improved overall and progression-free survival in pancreatic cancer.

Anti-CD19 CAR T-Cells Safe for Refractory Aggressive Non-Hodgkin Lymphoma

Anti-CD19 CAR T-Cells Safe for Refractory Aggressive Non-Hodgkin Lymphoma

By

Anti-CD19 chimeric antigen receptor (CAR) T-cells were determined to be safe for further study in patients with refractory aggressive non-Hodgkin lymphoma.

Neoadjuvant T-DM1 Plus Pertuzumab May Improve HER+ Breast Cancer Outcomes

Neoadjuvant T-DM1 Plus Pertuzumab May Improve HER+ Breast Cancer Outcomes

By

Neoadjuvant ado-trastuzumab emtansine (T-DM1) combined with pertuzumab substantially improved pathologic complete response rates.

Labetuzumab Govitecan Active in Heavily Pretreated mCRC

Labetuzumab Govitecan Active in Heavily Pretreated mCRC

By

Monotherapy with labetuzumab govitecan is active in heavily pretreated patients with metastatic colorectal cancer (mCRC).

Entinostat May Improve Benefit of High-dose IL-2 in RCC

Entinostat May Improve Benefit of High-dose IL-2 in RCC

By

Entinostat may synergistically improve the therapeutic effect of high dose interleukin-2 (IL-2) in treatment-naïve clear cell renal cell carcinoma (RCC).

Crizotinib Active in MET+ Papillary mRCC Type 1

Crizotinib Active in MET+ Papillary mRCC Type 1

By

Crizotinib induces objective responses and long-lasting disease control in metastatic papillary renal cell carcinoma type 1 (PRCC1).

Study Assesses Mechanisms Behind Ibrutinib Resistance in CLL

Study Assesses Mechanisms Behind Ibrutinib Resistance in CLL

By

Most patients with progressive chronic lymphocytic leukemia (CLL) receiving ibrutinib therapy harbor BTK and/or PLCG2 mutations.

PD-L1 Positivity Associated With Improved Efficacy of Pembrolizumab vs Ipilimumab

PD-L1 Positivity Associated With Improved Efficacy of Pembrolizumab vs Ipilimumab

By

Programmed death-ligand 1 (PD-L1) positivity is associated with improved efficacy with pembrolizumab in patients with advanced melanoma.

Pembrolizumab Resulted in Durable Responses in Advanced Merkel Cell Carcinoma

Pembrolizumab Resulted in Durable Responses in Advanced Merkel Cell Carcinoma

By

First-line therapy with pembrolizumab yielded frequent and durable response in patients with advanced Merkel cell carcinoma.

Nivolumab Improves Survival in Head and Neck Cancer

Nivolumab Improves Survival in Head and Neck Cancer

By

Nivolumab improved overall survival in patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Nivolumab Monotherapy Induces Durable, Long-term Survival in Advanced Melanoma

Nivolumab Monotherapy Induces Durable, Long-term Survival in Advanced Melanoma

By

After 5 years of follow-up, 34% of patients with advanced melanoma who participated in a phase 1 clinical trial are still alive after receiving nivolumab treatment.

Palbociclib Active in Patients With HR+/HER2- Early-stage Breast Cancer

Palbociclib Active in Patients With HR+/HER2- Early-stage Breast Cancer

By

Short-term pre-operative treatment with palbociclib significantly reduced Ki67 in treatment-naïve patients with early-stage breast cancer.

MammaPrint Test Reduces Use of Adjuvant Chemo Among Patients With Early-stage Breast Cancer

MammaPrint Test Reduces Use of Adjuvant Chemo Among Patients With Early-stage Breast Cancer

By

The MammaPrint genetic test can reduce the use of adjuvant chemotherapy following surgery among patients with early-stage breast cancer.

Circulating SAA, CXCL4 May Predict Osteosarcoma Outcome at Diagnosis

Circulating SAA, CXCL4 May Predict Osteosarcoma Outcome at Diagnosis

By

High serum amyloid A (SAA) and low CXC chemokine ligand 4 (CXCL4) at time of initial diagnosis are associated with poorer prognosis in osteosarcoma.

Early Negativization of BRAF V600 in cfDNA Linked to Excellent Prognosis in Melanoma

Early Negativization of BRAF V600 in cfDNA Linked to Excellent Prognosis in Melanoma

By

Patients with early negativization of BRAF V600 in tumor-derived circulating cell-free DNA (cfDNA) have excellent prognosis.

FGFR1 Overexpression Common in Adult Patients With Soft Tissue Sarcoma

FGFR1 Overexpression Common in Adult Patients With Soft Tissue Sarcoma

By

Fibroblast growth factor receptor 1 (FGFR1) amplification and overexpression are common events in multiple subtypes of soft tissue sarcoma.

Adding Bevacizumab to Chemoimmunotherapy Improves PFS in CLL

Adding Bevacizumab to Chemoimmunotherapy Improves PFS in CLL

By

Adding bevacizumab to front-line chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab (PCR) may be safe and effective.

IL17F-rs9463772 Predicts Long-term Outcome in Rectal Cancer

IL17F-rs9463772 Predicts Long-term Outcome in Rectal Cancer

By

Single nucleotide polymorphism (SNP) IL17F-rs9463772 represents a prognostic marker of long-term survival in locally advanced rectal cancer.

KRAS Mutation in cfDNA Linked to Response to Chemo in Pancreatic Cancer

KRAS Mutation in cfDNA Linked to Response to Chemo in Pancreatic Cancer

By

KRAS mutation in cell-free DNA (cfDNA) may be associated with treatment response to gemcitabine plus cisplatin chemotherapy in pancreatic cancer.

Pre-treatment Platelet Counts Associated With Prognosis in Stage 2-3 Rectal Cancer

Pre-treatment Platelet Counts Associated With Prognosis in Stage 2-3 Rectal Cancer

By

Platelet counts at the time of initial diagnosis had prognostic value for patients with rectal adenocarcinoma receiving neoadjuvant treatment.

Researchers Identify Potential Biomarkers for VEGFR TKIs in mRCC

Researchers Identify Potential Biomarkers for VEGFR TKIs in mRCC

By

Bcl-2 family member (BIM) expression and phosphoinositide 3 kinase R1 (PIK3R1) might be candidate biomarkers for renal cell carcinoma (mRCC).

Circulating FGF21 Found To Be a Diagnostic, Prognostic Marker in RCC

Circulating FGF21 Found To Be a Diagnostic, Prognostic Marker in RCC

By

Serum fibroblast growth factor 21 (FGF21) is useful as a diagnostic and prognostic biomarker in patients with clear cell renal cell carcinoma (ccRCC).

Potential Biomarkers Identified for Patients With Prostate Cancer Treated With SBRT

Potential Biomarkers Identified for Patients With Prostate Cancer Treated With SBRT

By

Molecular pathways identified that may serve as potential biomarkers in prostate cancer treated with stereotactic body radiation therapy (SBRT).

Metformin Enhances Activity of Abiraterone, Enzalutamide

Metformin Enhances Activity of Abiraterone, Enzalutamide

By

Metformin, a widely used oral anti-diabetic drug, enhanced the anti-prostate cancer activity of abiraterone and enzalutamide.

Adding XPO1 Inhibitors to Melphalan May Improve Response in Myeloma

Adding XPO1 Inhibitors to Melphalan May Improve Response in Myeloma

By

Adding an XPO1 inhibitor, such as selinexor, to melphalan may significantly improve the treatment outcomes of patients with multiple myeloma.

BRCA1, AEG1 Expression Do Not Impact Outcomes in Patients With NSCLC Receiving Erlotinib, Bevacizumab

BRCA1, AEG1 Expression Do Not Impact Outcomes in Patients With NSCLC Receiving Erlotinib, Bevacizumab

By

BRCA1 and AEG1 mRNA expression levels do not significantly impact median progression-free survival in non-small cell lung cancer (NSCLC).

Co-targeting Pathways May Improve Efficacy of EGFR-TKIs in Lung Cancer

Co-targeting Pathways May Improve Efficacy of EGFR-TKIs in Lung Cancer

By

Treatment with a single epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) can no longer be considered adequate.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs